Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity

Journal of Neurochemistry

Volumn 103, Issue 5, 2007, Pages 2058-2065

  Hu, Yongjun ^a   Shen, Hong ^a,b   Keep, Richard F ^a   Smith, David E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

5 aminolevulinic acid; Brain; Expression; Neurotoxicity; Peptide transporter 2

Indexed keywords

AMINOLEVULINIC ACID; LEAD; PEPTIDE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; CEREBROSPINAL FLUID; CHOROID PLEXUS; CONTROLLED STUDY; HEPATIC PORPHYRIA; LEAD POISONING; MOUSE; NEUROMODULATION; NEUROMUSCULAR DISEASE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; WILD TYPE;

AMINOLEVULINIC ACID; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; MICE; MICE, KNOCKOUT; NEUROMUSCULAR JUNCTION; NEUROTOXICITY SYNDROMES; PHOTOSENSITIZING AGENTS; SYMPORTERS; TISSUE DISTRIBUTION;

ANIMALIA; MUS;

EID: 36248954510     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04905.x     Document Type: Article

References (32)

1. A receptor density in neuronal cells, synaptosomes and rat brain. Brain Res. 1093, 95 104.
2. Albers J. W. Fink J. K. (2004) Porphyric neuropathy. Muscle Nerve 30, 410 422.
3. Anderson K. E., Sassa S., Bishop D. F. Desnick R. J. (2001) Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias, in The Metabolic & Molecular Bases of Inherited Disease (Scriver C. R., Beaudet A. L., Sly W. S. Valle D., eds pp. 2991 3062. McGraw-Hill, New York.
4. Capecchi M. R. (1994) Targeted gene replacement. Sci. Am. 270, 52 59.
5. Daniel H. Kottra G. (2004) The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. 447, 610 618.
6. Daniel H. Rubio-Aliaga I. (2003) An update on renal peptide transporters. Am. J. Physiol. 284, F885 F892.
7. Döring F., Walter J., Will J., Föcking M., Boll M., Amasheh S., Clauss W. Daniel H. (1998) Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J. Clin. Invest. 101, 2761 2767.
8. Edwards S. R., Shanley B. C. Reynoldson J. A. (1984) Neuropharmacology of delta-aminolaevulinic acid-I: effect of acute administration in rodents. Neuropharmacology 23, 477 481.
9. Elmquist W. F. Miller D. W. (2001) The use of transgenic mice in pharmacokinetic and pharmacodynamic studies. J. Pharm. Sci. 90, 422 435.
10. -/- mice. Physiol. Genomics 28, 301 310.
11. Gorchein A. Webber R. (1987) δ-Aminolevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects. Clin. Sci. 72, 103 112.
12. Jonker J. W., Buitelaar M., Wagenaar E. et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl Acad. Sci. USA 99, 15649 15654.
13. Kazemi H. Johnson D. C. (1986) Regulation of cerebrospinal fluid acid-base balance. Physiol. Rev. 66, 953 1037.
14. Keep R. F. Smith D. E. (2006) Oligopeptide transport at the blood-brain and blood-CSF barriers, in Handbook of Biologically Active Peptides (Kastin A. J., ed pp. 1423 1428. Elsevier, Amsterdam, Holland.
15. Keep R. F., Si X., Shakui P., Ennis S. R. Betz A. L. (1999) Effect of amiloride analogs on DOCA-salt-induced hypertension in rats. Am. J. Physiol. 276, H2215 H2220.
16. Klaassen C. D. (2006) Heavy metals and heavy-metal antagonists, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton L. L., Lazo J. S. Parker K. L., eds pp. 1753 1775. McGraw-Hill, New York.
17. Lindberg R. L. P., Martini R., Baumgartner M. et al. (1999) Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J. Clin. Invest. 103, 1127 1134.
18. Novotny A., Xiang J., Stummer W., Teuscher N. S., Smith D. E. Keep R. F. (2000) Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. J. Neurochem. 75, 321 328.
19. Ocheltree S. M., Shen H., Hu Y., Xiang J., Keep R. F. Smith D. E. (2004) Role of PEPT2 in the choroid plexus uptake of glycylsarcosine and 5-aminolevulininc acid: studies in wild-type and null mice. Pharm. Res. 21, 1680 1685.
20. Ocheltree S. M., Shen H., Hu Y., Keep R. F. Smith D. E. (2005) Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J. Pharmacol. Exp. Ther. 315, 240 247.
21. Pinsonneault J., Nielsen C. U. Sadée W. (2004) Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J. Pharmacol. Exp. Ther. 311, 1088 1096.
22. Rubio-Aliaga I., Frey I., Boll M., Groneberg D. A., Eichinger H. M., Balling R. Daniel H. (2003) Targeted disruption of the peptide transporter Pept2 gene in mice defined its physiological role in the kidney. Mol. Cell. Biol. 23, 3247 3252.
23. Schinkel A. H., Smit J. J. M., van Tellingen O. et al. (1994) Disruption of the mouse mdr1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491 502.
24. Shen H., Smith D. E., Yang T., Huang Y. G., Schnermann J. B. Brosius F. C. III. (1999) Localization of PEPT1 and PEPT2 proton-couple oligopeptide transporter mRNA and protein in rat kidney. Am. J. Physiol. 276, F658 F664.
25. Shen H., Smith D. E., Keep R. F., Xiang J. Brosius F. C. III. (2003) Targeted disruption of the PEPT2 gene markedly reduces dipeptide uptake in choroid plexus. J. Biol. Chem. 278, 4786 4791.
26. Shen H., Smith D. E., Keep R. F. Brosius F. C. III. (2004) Immunolocalization of the proton-coupled oligopeptide transporter PEPT2 in developing rat brain. Mol. Pharm. 1, 248 256.
27. Shen H., Ocheltree S., Hu Y., Keep R. F. Smith D. E. (2007) Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption and brain penetration in mice. Drug Metab. Dispos. 35, 1209 1216
28. Shiogai T., Nara I., Saruta K., Hara M. Saito I (1999) Continuous monitoring of cerebrospinal fluid acid-base balance and oxygen metabolism in patients with severe head injury: pathophysiology and treatments for cerebral acidosis and ischemia. Acta Neurochir. Suppl. 75, 49 55.
29. Smith D. E., Johanson C. E. Keep R. F. (2004) Peptide and peptide analog transport systems at the blood-CSF barrier. Adv. Drug Deliv. Rev. 56, 1765 1791.
30. Terada T., Irie M., Okuda M. Inui K. (2004) Genetic variant Arg57His in human H+/peptide cotransporter 2 causes a complete loss of transport function. Biochem. Biophys. Res. Commun. 316, 416 420.
31. Teuscher N. S., Shu C., Xiang J., Keep R. F. Smith D. E. (2004) Carnosine uptake in rat choroid plexus primary cell cultures and choroid plexus whole tissue from PEPT2 null mice. J. Neurochem. 89, 375 382.
32. Wang L., Yan D., Gu Y., Sun L.-G. Ruan D.-Y. (2005) Effects of extracellular δ-aminolaevulinic acid on sodium currents in acutely isolated rat hippocampal CA1 neurons. Eur. J. Neurosci. 22, 3122 3128.